Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CD19/BCMA CAR-T in R/R Autoimmune Diseases
NCT06941129Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), inflammatory myopathy (IIM) and 2 more, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 12 months and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)inflammatory myopathy (IIM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)Thrombocytopenia
Beyond the preview
Go deeper on NCT06941129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941129.